Randolf Brehler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Randolf Brehler has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Margitta Worm
Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy Charité—University Medical Center Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität Zu Berlin Berlin Germany
10 shared publications - Ludger Klimek
Department of Otolaryngology, Head and Neck Surgery Universitätsmedizin Mainz Mainz Germany
9 shared publications - Thomas Werfel
Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany
8 shared publications - Eckard Hamelmann
Children’s Center Bethel, Protestant Hospital Bethel, University Hospital OWL, University of Bielefeld, Bielefeld, Germany
7 shared publications - Thomas Fuchs
Georg August Univ, Univ Med Gottingen, Klin Dermatol Venerol & Allergol, Gottingen, Germany
7 shared publications - Christian Taube
Department of Pneumology, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany
6 shared publications
Latest Publications
- 7 October 2025
- Published by Springer Nature
- p. 1-7
Beekeepers
- Open Access
- 15 July 2024
- Published by Springer Nature in Allergo Journal International
- Vol. 33 (5) , 159-164
Physician’s perspectives on skin prick testing and allergy diagnostics in Germany
Summary: Purpose: Novel technologies standardising the testing process of immediate hypersensitivities have been developed and validated in recent years. Meanwhile, challenges with regard to availability of testing agents and shortage of trained personnel have increased. Novel technologies could fight these challenges, but their distribution is at present not known. The current survey, conducted by the German Society for Allergology (AeDA), aimed to assess current practices of allergy diagnostics in Germany. Methods: Members of AeDA were invited to complete an online questionnaire to obtain information on their perspectives on allergy testing and diagnostics. Results: A total of 150 allergologists from different disciplines treating patients with allergy completed the questionnaire. This survey revealed that twice as many skin prick tests (SPT; 21.2 tests/week) compared to serum specific immunoglobulin E tests (IgE; 10.4 tests/week) are being performed. Nasal allergen provocation tests are being performed in 56.0% of hospitals and physicians’ offices. An individual standard allergen panel for SPT is applied in 78.0% of testing cases. Methods used to perform a read out of SPT are variable with measurement of the longest wheal diameter being used most frequently (68.0%), followed by a qualitative evaluation (46.6%) or the longest wheal diameter including pseudopods (34.4%). In all, 66% of allergologists indicated that a device that automating the SPT process would be valuable for clinical practice. Conclusion: Skin prick tests and serum IgE tests are still the cornerstones in the diagnostic work-up of immediate-type allergies. Variability in the execution of skin prick tests exists between different hospitals and physicians’ offices in Germany. Inconsistent availability of testing reagents was considered most problematic for maintaining allergy diagnostics in Germany. A majority of allergologists are open to evaluating tools that may contribute to standardize skin prick tests.
- 15 July 2024
- Published by Springer Nature in Allergo Journal International
- Vol. 33 (5) , 159-164
Open AccessPhysician’s perspectives on skin prick testing and allergy diagnostics in Germany
Summary: Purpose: Novel technologies standardising the testing process of immediate hypersensitivities have been developed and validated in recent years. Meanwhile, challenges with regard to availability of testing agents and shortage of trained personnel have increased. Novel technologies could fight these challenges, but their distribution is at present not known. The current survey, conducted by the German Society for Allergology (AeDA), aimed to assess current practices of allergy diagnostics in Germany. Methods: Members of AeDA were invited to complete an online questionnaire to obtain information on their perspectives on allergy testing and diagnostics. Results: A total of 150 allergologists from different disciplines treating patients with allergy completed the questionnaire. This survey revealed that twice as many skin prick tests (SPT; 21.2 tests/week) compared to serum specific immunoglobulin E tests (IgE; 10.4 tests/week) are being performed. Nasal allergen provocation tests are being performed in 56.0% of hospitals and physicians’ offices. An individual standard allergen panel for SPT is applied in 78.0% of testing cases. Methods used to perform a read out of SPT are variable with measurement of the longest wheal diameter being used most frequently (68.0%), followed by a qualitative evaluation (46.6%) or the longest wheal diameter including pseudopods (34.4%). In all, 66% of allergologists indicated that a device that automating the SPT process would be valuable for clinical practice. Conclusion: Skin prick tests and serum IgE tests are still the cornerstones in the diagnostic work-up of immediate-type allergies. Variability in the execution of skin prick tests exists between different hospitals and physicians’ offices in Germany. Inconsistent availability of testing reagents was considered most problematic for maintaining allergy diagnostics in Germany. A majority of allergologists are open to evaluating tools that may contribute to standardize skin prick tests.
- 10 June 2024
- Published by Springer Nature in Allergo Journal
- Vol. 33 (4) , 16-23
Allergenspezifische Immuntherapie bei Schimmelpilzallergien
- 10 June 2024
- Published by Springer Nature in Allergo Journal
- Vol. 33 (4) , 16-23
Allergenspezifische Immuntherapie bei Schimmelpilzallergien
- 2 May 2024
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 47 (05) , 253-261
Diagnose der Tierhaarallergie und klinische Relevanz von IgE-Profilen
- 2 May 2024
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 47 (05) , 253-261
Diagnose der Tierhaarallergie und klinische Relevanz von IgE-Profilen
- Open Access
- 23 April 2024
- Published by Springer Nature in Allergo Journal International
- Vol. 33 (4) , 101-105
Allergen-specific immunotherapy for mold allergies
- 23 April 2024
- Published by Springer Nature in Allergo Journal International
- Vol. 33 (4) , 101-105
Open AccessAllergen-specific immunotherapy for mold allergies
- Open Access
- 24 November 2022
- Published by Springer Nature in Allergo Journal International
- Vol. 32 (1) , 5-9
Allergen characteristics, quality, major allergen content and galenics for mite allergen-specific immunotherapy preparations
Summary: House dust mite extracts for allergen-specific immunotherapy (AIT) require in Germany as other common allergens (pollen from sweet grasses [except maize], birch, alder, hazel; bee and wasp venom) marketing authorisation according to the German Therapy Allergen Ordinance (“Therapieallergene-Verordnung”, [TAV]). Mite allergen extracts that have been approved and also those which are in the approval process are subject to government batch testing. Batch test passing is a prerequisite for marketability. Appropriate quality, efficacy, and safety are prerequisites for the approval of house dust mite extracts. Five HDM allergen extracts from four manufacturers are currently approved in Germany for subcutaneous or sublingual therapy; further extracts are in the approval process. The allergen strength of different products is not comparable; manufacturers use company-specific units to describe the strength. Of the three known major allergens (Group 1 allergens: Der p 1, Der f 1, Group 2 allergens: Der p 2, Der f 2 and Group 23: Der p 23, Der f 23) only Group 1 and Group 2 allergens are usually used to standardize the extracts. Group 23 allergens are localized in the outer membrane of mite faeces, and elution requires special extraction methods. To be efficacious in a single patient an allergen extracts used for AIT must contain all allergen components against which the patient is sensitised. Based on post hoc analyses of large clinical studies, it has been proven for house dust mite tablets that Der p 23 is also contained. In Germany, the Paul Ehrlich Institute is responsible for the approval of therapeutic allergens. For the marketing authorisation information on production procedures, and quality are necessary efficacy and safety (positive benefit risk ratio) of the product must be demonstrated in clinical trials according to the current state of the art.
- 24 November 2022
- Published by Springer Nature in Allergo Journal International
- Vol. 32 (1) , 5-9
Open AccessAllergen characteristics, quality, major allergen content and galenics for mite allergen-specific immunotherapy preparations
Summary: House dust mite extracts for allergen-specific immunotherapy (AIT) require in Germany as other common allergens (pollen from sweet grasses [except maize], birch, alder, hazel; bee and wasp venom) marketing authorisation according to the German Therapy Allergen Ordinance (“Therapieallergene-Verordnung”, [TAV]). Mite allergen extracts that have been approved and also those which are in the approval process are subject to government batch testing. Batch test passing is a prerequisite for marketability. Appropriate quality, efficacy, and safety are prerequisites for the approval of house dust mite extracts. Five HDM allergen extracts from four manufacturers are currently approved in Germany for subcutaneous or sublingual therapy; further extracts are in the approval process. The allergen strength of different products is not comparable; manufacturers use company-specific units to describe the strength. Of the three known major allergens (Group 1 allergens: Der p 1, Der f 1, Group 2 allergens: Der p 2, Der f 2 and Group 23: Der p 23, Der f 23) only Group 1 and Group 2 allergens are usually used to standardize the extracts. Group 23 allergens are localized in the outer membrane of mite faeces, and elution requires special extraction methods. To be efficacious in a single patient an allergen extracts used for AIT must contain all allergen components against which the patient is sensitised. Based on post hoc analyses of large clinical studies, it has been proven for house dust mite tablets that Der p 23 is also contained. In Germany, the Paul Ehrlich Institute is responsible for the approval of therapeutic allergens. For the marketing authorisation information on production procedures, and quality are necessary efficacy and safety (positive benefit risk ratio) of the product must be demonstrated in clinical trials according to the current state of the art.
- Open Access
- 24 November 2022
- Published by Springer Nature in Allergo Journal International
- Vol. 32 (1) , 1-4
Clinic and diagnostics of house dust mite allergy
Summary: House dust mite allergens are common triggers for allergic rhinoconjunctivitis and allergic asthma; they can aggravate atopic dermatitis and rarely lead to anaphylactic reactions due to dust mite allergens in food. Typical symptoms are nasal obstruction, sneezing, and irritation, and more often than in pollen allergy, allergic asthma also develops. The symptomatology exists in principle throughout the year with maximum complaints in autumn and winter. Of particular importance are sleep disturbances due to nasal obstruction, which lead to restrictions in the quality of life and performance of affected patients. Sensitization can be proven by skin tests and detection of serum allergen-specific IgE antibodies; proof of allergy is achieved by nasal or conjunctival provocation tests. The diagnosis of local allergic rhinitis can only be made by provocation or by determination of allergen-specific IgE antibodies in nasal secretions. The quality of the allergen extract used is essential for all tests; it must contain the allergens to which a patient is sensitized. The concentration of Der p 23 in house dust mite extracts is particularly critical.
- 24 November 2022
- Published by Springer Nature in Allergo Journal International
- Vol. 32 (1) , 1-4
Open AccessClinic and diagnostics of house dust mite allergy
Summary: House dust mite allergens are common triggers for allergic rhinoconjunctivitis and allergic asthma; they can aggravate atopic dermatitis and rarely lead to anaphylactic reactions due to dust mite allergens in food. Typical symptoms are nasal obstruction, sneezing, and irritation, and more often than in pollen allergy, allergic asthma also develops. The symptomatology exists in principle throughout the year with maximum complaints in autumn and winter. Of particular importance are sleep disturbances due to nasal obstruction, which lead to restrictions in the quality of life and performance of affected patients. Sensitization can be proven by skin tests and detection of serum allergen-specific IgE antibodies; proof of allergy is achieved by nasal or conjunctival provocation tests. The diagnosis of local allergic rhinitis can only be made by provocation or by determination of allergen-specific IgE antibodies in nasal secretions. The quality of the allergen extract used is essential for all tests; it must contain the allergens to which a patient is sensitized. The concentration of Der p 23 in house dust mite extracts is particularly critical.
- 18 February 2022
- Published by Springer Nature in HNO Nachrichten
- Vol. 52 (1) , 20-27
Allergien auf Impfstoffe: Ein wichtiges Feld auch für HNO-Ärzte
- 18 February 2022
- Published by Springer Nature in HNO Nachrichten
- Vol. 52 (1) , 20-27
Allergien auf Impfstoffe: Ein wichtiges Feld auch für HNO-Ärzte
- 13 August 2021
- Published by Springer Nature in Allergo Journal
- Vol. 30 (5) , 24-33
COVID-19-Impfungen von Patienten mit Allergien und Typ2-entzündlichen Erkrankungen bei gleichzeitiger Antikörpertherapie (Biologika)
- 13 August 2021
- Published by Springer Nature in Allergo Journal
- Vol. 30 (5) , 24-33
COVID-19-Impfungen von Patienten mit Allergien und Typ2-entzündlichen Erkrankungen bei gleichzeitiger Antikörpertherapie (Biologika)
- 7 May 2021
- Published by Springer Nature in Allergo Journal
- Vol. 30 (3) , 22-43
Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe
Hintergrund: Zur vorbeugenden Behandlung von COVID-19 (Coronaviruserkrankung 2019) wurden in einer beispiellosen weltweiten Forschungsanstrengung …
- 7 May 2021
- Published by Springer Nature in Allergo Journal
- Vol. 30 (3) , 22-43
Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe
Hintergrund: Zur vorbeugenden Behandlung von COVID-19 (Coronaviruserkrankung 2019) wurden in einer beispiellosen weltweiten Forschungsanstrengung …